CVRX · CVRx, Inc.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Vests as to one-third of the shares on each annual anniversary of the date of grant.

Vests as to one-third of the shares on each annual anniversary of the date of grant.

Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Reflects the weighted average price of 1,262 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Reflects the weighted average price of 7,763 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Reflects the weighted average price of 1,284 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $7.98 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Vests as to 25% of the shares on March 2, 2027 and as to 1/48th of the shares each month thereafter.

The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Reflects the weighted average price of 1,744 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $7.9831 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.

Reflects the weighted average price of 3,964 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $7.994 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.

Includes 1,840 shares acquired under Issuer's Employee Stock Purchase Plan.

Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.

Reflects the weighted average price of 46,800 shares of common stock of CVRx, Inc. purchased by the reporting person in multiple transactions on February 20, 2026 with purchase prices ranging from $5.8500 to $6.3868 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These shares are held directly by Treo Ventures I, L.P ("Treo"). The Reporting Person is the General Partner of Treo and shares voting and dispositive power over the shares held by Treo. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares.

Reflects the weighted average price of 600 shares of common stock of CVRx, Inc. purchased by the reporting person in multiple transactions on February 18, 2026 with purchase prices ranging from $4.63 to $4.65 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.10. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The price reported in Column 4 is a weighted average price. 29 shares were sold at $10.04 and 971 shares were sold at $10.00.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.49. The Reporting Persons undertake to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.

Restricted stock units that vest 25% on each anniversary of the grant date

Stock options that vest 25% on the first annual anniversary of the date of grant and then 1/48th per month thereafter.

Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders.

Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders.

Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders.